185 related articles for article (PubMed ID: 21955615)
21. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
Ozkaynak MF; Krailo M; Chen Z; Feusner J
Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
[TBL] [Abstract][Full Text] [Related]
22. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.
Bucaneve G; Micozzi A; Menichetti F; Martino P; Dionisi MS; Martinelli G; Allione B; D'Antonio D; Buelli M; Nosari AM; Cilloni D; Zuffa E; Cantaffa R; Specchia G; Amadori S; Fabbiano F; Deliliers GL; Lauria F; Foà R; Del Favero A;
N Engl J Med; 2005 Sep; 353(10):977-87. PubMed ID: 16148283
[TBL] [Abstract][Full Text] [Related]
23. Colony-stimulating factors as an adjunct to chemotherapy in small cell lung cancer.
Urban T; Schuller MP; Lebeau B
Eur Respir J; 1996 Mar; 9(3):596-602. PubMed ID: 8730024
[TBL] [Abstract][Full Text] [Related]
24. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.
Cullen M; Steven N; Billingham L; Gaunt C; Hastings M; Simmonds P; Stuart N; Rea D; Bower M; Fernando I; Huddart R; Gollins S; Stanley A;
N Engl J Med; 2005 Sep; 353(10):988-98. PubMed ID: 16148284
[TBL] [Abstract][Full Text] [Related]
25. Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee.
Slavin MA; Lingaratnam S; Mileshkin L; Booth DL; Cain MJ; Ritchie DS; Wei A; Thursky KA;
Intern Med J; 2011 Jan; 41(1b):102-9. PubMed ID: 21272174
[TBL] [Abstract][Full Text] [Related]
26. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials.
Clark OA; Lyman GH; Castro AA; Clark LG; Djulbegovic B
J Clin Oncol; 2005 Jun; 23(18):4198-214. PubMed ID: 15961767
[TBL] [Abstract][Full Text] [Related]
27. Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
Waladkhani AR
Eur J Cancer Care (Engl); 2004 Sep; 13(4):371-9. PubMed ID: 15305906
[TBL] [Abstract][Full Text] [Related]
28. Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?
Klastersky J; Awada A
Crit Rev Oncol Hematol; 2011 Apr; 78(1):17-23. PubMed ID: 20227290
[TBL] [Abstract][Full Text] [Related]
29. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
Weycker D; Hackett J; Edelsberg JS; Oster G; Glass AG
Ann Pharmacother; 2006 Mar; 40(3):402-7. PubMed ID: 16492793
[TBL] [Abstract][Full Text] [Related]
30. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Pilot study phase I.
Mego M; Ebringer L; Drgona L; Mardiak J; Trupl J; Greksak R; Nemova I; Oravcova E; Zajac V; Koza I
Neoplasma; 2005; 52(2):159-64. PubMed ID: 15800715
[TBL] [Abstract][Full Text] [Related]
31. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?
Adams JR; Angelotta C; Bennett CL
J Clin Oncol; 2006 Jul; 24(19):2975-7. PubMed ID: 16682722
[No Abstract] [Full Text] [Related]
32. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
Ohnoshi T; Ueoka H; Kodani T; Kamei H; Kimura I
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 2):911-8. PubMed ID: 1693062
[TBL] [Abstract][Full Text] [Related]
33. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
Johnston EM; Crawford J
Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594
[TBL] [Abstract][Full Text] [Related]
34. [Guidelines for prevention of febrile neutropenia].
Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
[TBL] [Abstract][Full Text] [Related]
35. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome.
Lee JH; Lee KH; Lee JH; Kim DY; Kim SH; Lim SN; Kim SD; Choi Y; Lee SM; Lee WS; Choi MY; Joo YD
Leuk Res; 2011 Apr; 35(4):499-503. PubMed ID: 20674021
[TBL] [Abstract][Full Text] [Related]
36. Management of chemotherapy-induced neutropenia in the older cancer patient.
Balducci L
Oncology (Williston Park); 2006 Dec; 20(14 Suppl 9):26-31. PubMed ID: 17370926
[TBL] [Abstract][Full Text] [Related]
37. Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005-2017.
Schenfeld JR; Bennett CW; Li S; DeCosta LJ; Jaramillo RR; Gawade PL
J Oncol Pharm Pract; 2021 Jan; 27(1):128-142. PubMed ID: 32326872
[TBL] [Abstract][Full Text] [Related]
38. Myelosuppression and its consequences in elderly patients with cancer.
Balducci L
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):27-32. PubMed ID: 14682116
[TBL] [Abstract][Full Text] [Related]
39. The importance of prophylactic management of chemotherapy-induced neutropenia.
Repetto L; Accettura C
Anticancer Drugs; 2003 Oct; 14(9):725-30. PubMed ID: 14551505
[TBL] [Abstract][Full Text] [Related]
40. Editorial comments on 'Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'.
Bunn PA
Ann Oncol; 2001 Oct; 12(10):1339-40. PubMed ID: 11762802
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
